SYMDEKO is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.

Materials and resources for healthcare professionals:

F508del Homozygous Clinical Trial Overview Brochure

Review information about patients with CF who are homozygous for the F508del mutation.

Clinical Results
Download

Clinical Brochure

Review information about efficacy, safety, DDIs, and dosing.

Clinical Results
Download

Initiation Guide

Review considerations for initiating SYMDEKO.

Initation Guide
Download

Mutation Card

See all indicated mutations for SYMDEKO.

Mutation Card
Download

Materials for you to share with your patients:

SYMDEKO Safety Overview

Provide patients with information about SYMDEKO safety and side effects

Safety
Download

Guide to Taking SYMDEKO Brochure

Provide patients with information about how to take SYMDEKO and the importance of taking it with fat-containing foods.

How to Take SYMDEKO® (tezacaftor/ivacaftor and ivacaftor)
Download

SYMDEKO Brochure

Help patients learn how SYMDEKO works, and see study details, results, and possible side effects.

Results
Download